RxDoctor Payments DataLook up a doctor →

Henry Paik, MD

Gastroenterology · Chattanooga, TNNPI 1194789149

Payments from drug & device makers

$19,057in general payments, 2019–2025

Across 1,001 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Johnson & Johnson$1K
  • Gilead$754
  • Pfizer$600
  • plus $6K from 35 others

What the payments were for

  • Food & beverage$18,76298%
  • Education$1471%
  • Gifts$1471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,057 in reported general payments places this provider in the 80th percentile of 336 gastroenterology providers in Tennessee.

See all gastroenterology providers in Tennessee

Medicare billing

Part B allowed, 2024
$128,803
Medicare patients
544
Services billed
1,367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab48$672,749
Skyrizi On-BodyRisankizumab-Rzaa14$282,504
OcalivaObeticholic Acid19$184,149
XifaxanRifaximin53$173,468
LinzessLinaclotide173$146,604
RezdiffraResmetirom12$55,757
CreonLipase/Protease/Amylase19$49,448
ZenpepLipase/Protease/Amylase29$38,036
IbsrelaTenapanor Hcl22$37,892
Dexlansoprazole DrDexlansoprazole111$37,720
ViberziEluxadoline14$20,015
VoqueznaVonoprazan Fumarate18$17,125
ClenpiqSod Picosulf/Mag Ox/Citric Ac66$11,163
Dicyclomine Hcl296$7,824
Omeprazole423$7,794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon, Viberzi$5,789$216,067206 claims
Intercept Pharmaceuticals, Inc.Ocaliva$453$184,14919 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$2,952$179,51565 claims
Madrigal PharmaceuticalsRezdiffra$503$55,75712 claims
Aimmune Therapeutics, Inc.Zenpep$332$38,03629 claims
Ardelyx, Inc.Ibsrela$179$37,89222 claims
Phathom Pharmaceuticals, Inc.Voquezna$173$17,12518 claims
Ferring Pharmaceuticals Inc.Clenpiq$311$11,16366 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 336 gastroenterology providers in Tennessee.

Other gastroenterology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →